May 2008- Volume 4, Issue 5

May 2008

In this Issue

Automation & Instrumentation

A “mito” distribution deal

A “mito” distribution deal

Invitrogen gets exclusive distribution rights for MitoSciences’ monoclonal antibodies and immunoassays

Member benefits

Member benefits

Pennsylvania Bio inks supply deal with Fisher Scientific

ANTIBODY TRANSFER

ANTIBODY TRANSFER

MitoSciences gains access to University of Oregon’s monoclonal antibody portfolio

Comprehensive custom services

Comprehensive custom services

PerkinElmer, Cerep team up to market assay development, screening services

Global News

Collaboration is easy on the eyes

Collaboration is easy on the eyes

Jerini Ophthalmic and PR Pharmaceuticals to develop sustained-release formulations for eye diseases

Informatics

VERTICAL*I GOES LATERAL

VERTICAL*I GOES LATERAL

Company joins forces with Thomson Scientific to provide end-to-end solutions for business development

Pfizer picks pathway partner

Pfizer picks pathway partner

Ingenuity Systems to implement integrated IPA software for pharma giant

Virtual diabetes research

Virtual diabetes research

ADA and Entelos open access to in silico testing with virtual mice

Genomics & Proteomics

Exploring new territory

Exploring new territory

Celera inks two-year license agreement with Merck to develop RNAi-based therapeutics

Bringing it back home

Bringing it back home

Affymetrix extends Collaborations in Cancer Research Program to North American region

Raising hopes

Raising hopes

Helicos enters collaboration to sequence cancer-associated genes

Research & Development

Synthetic biology gets a boost

Synthetic biology gets a boost

Codon Devices to engineer protein drug for Merrimack Pharmaceuticals

Building better bones

Building better bones

Merck, Harvard to advance osteoporosis research

NIEHS, U. Minn. study may lead to improved epilepsy treatments

NIEHS, U. Minn. study may lead to improved epilepsy treatments

Researchers from the National Institute of Environmental Health Sciences (NIEHS) and the University of Minnesota have gained new insight into one of the most puzzling aspects of epilepsy treatment: why some epileptics fail to respond to anti-epileptic medications.

Partners in Parkinson’s

Partners in Parkinson’s

Buck Institute and Q Therapeutics form stem cell collaboration to combat Parkinson’s Disease
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue